mefloquine has been researched along with physostigmine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Coakley, KM; Hognason, K; McArdle, JJ; Potian, JG; Quinones-Lopez, MC; Rosenfeld, CA; Sellin, LC; Sultatos, LG | 1 |
1 review(s) available for mefloquine and physostigmine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for mefloquine and physostigmine
| Article | Year |
|---|---|
Mefloquine inhibits cholinesterases at the mouse neuromuscular junction.
Topics: Acetylcholinesterase; Animals; Antimalarials; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Electrophysiology; Humans; Mefloquine; Membrane Potentials; Mice; Mice, Knockout; Motor Endplate; Neuromuscular Junction; Parasympathetic Nervous System; Physostigmine; Synapses | 2005 |